Israeli generics giant Teva Pharmaceutical Industries announced on 1 March 2017 the launch of generic desvenlafaxine extended-release tablets in dosages of 25, 50 and 100 mg, in the US.

On 2 March 2017, Indian generics maker Lupin Pharmaceuticals announced the launch of generic desvenlafaxine extended-release tablets in the 50 and 100 mg dosages, after having received approval from the US Food and Drug Administration (FDA).

Finally, this was followed by an announcement by US-based drugmaker Mylan on 10 March 2017. Mylan has also launched 50 and 100 mg dosages of desvenlafaxine extended-release tablets in the US.

According to IMS Health data the 50 and 100 mg dosages of desvenlafaxine extended-release tablets had US sales of approximately US$853 million for the 12 months ending 31 January 2017.

Pfizer is also expected to take losses when its blockbuster erectile dysfunction drug Viagra (sildenafil) also loses patent protection and faces generics competition at the end of 2017.

Related article
No difference between generic and brand-name antidepressants

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.